These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22621454)

  • 21. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aceclofenac-induced acute cholestatic lesion].
    Titos-Arcos JC; Hallal H; Andrade RJ; Gálvez J
    Gastroenterol Hepatol; 2010 May; 33(5):417-8. PubMed ID: 20206408
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC; Ashcroft DM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advice for nurses on drug withdrawal.
    Aust Nurs J; 2007 Sep; 15(3):8. PubMed ID: 17891987
    [No Abstract]   [Full Text] [Related]  

  • 27. Australian drugs regulator cancels registration of COX 2 inhibitor.
    Burton B
    BMJ; 2007 Aug; 335(7616):363. PubMed ID: 17717345
    [No Abstract]   [Full Text] [Related]  

  • 28. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of lumiracoxib when used in the treatment of arthritis.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Feb; 6(2):347-50. PubMed ID: 15757430
    [No Abstract]   [Full Text] [Related]  

  • 30. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology.
    Hinz B; Brune K
    Trends Pharmacol Sci; 2008 Aug; 29(8):391-7. PubMed ID: 18606461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Acute Myocardial Infarction Induced by Selective Cyclooxygenase-2 Inhibitor.
    Seo KW; Park JS; Tahk SJ; Shin JH
    Chin Med J (Engl); 2017 May; 130(9):1131-1132. PubMed ID: 28469113
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
    Li Y; Slatter JG; Zhang Z; Li Y; Doss GA; Braun MP; Stearns RA; Dean DC; Baillie TA; Tang W
    Drug Metab Dispos; 2008 Feb; 36(2):469-73. PubMed ID: 17998295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
    Syed M; Skonberg C; Hansen SH
    Toxicol In Vitro; 2016 Apr; 32():26-40. PubMed ID: 26689325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment].
    Schmidt M; Fosbøl EL; Torp-Pedersen C; Olsen AS; Christensen B; Gislason GH
    Ugeskr Laeger; 2016 Dec; 178(52):. PubMed ID: 28041549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats.
    Ortiz MI; Castañeda-Hernández G
    Eur J Pain; 2008 Feb; 12(2):233-41. PubMed ID: 17606391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.
    Sheldon EA; Beaulieu A; Paster Z; Yu S; Rebuli R
    Clin Exp Rheumatol; 2008; 26(4):611-9. PubMed ID: 18799092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute hepatitis caused by diclofenac].
    Vilà Santasuana A; Cid Pañella R; Roure Nuez C; Martínez Montauti J; Ortega Enciso YL
    Gastroenterol Hepatol; 1997 Mar; 20(3):164-5. PubMed ID: 9162541
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The hepatotoxic effect of nonsteroidal anti-inflammatory preparations].
    Polunina TE; Fomichev VI; Vasil'ev AP
    Ter Arkh; 1994; 66(5):79-80. PubMed ID: 7940350
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.